Skip to content

Promoting Activity, Independence and Stability in Early Dementia and Mild Cognitive Impairment

Promoting Activity, Independence and Stability in Early Dementia and Mild Cognitive Impairment

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04065854
Acronym
PrAISED2
Enrollment
368
Registered
2019-08-22
Start date
2018-10-01
Completion date
2022-03-13
Last updated
2019-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia, Mild Cognitive Impairment

Brief summary

A clinical trial to test the clinical and cost-effectiveness of a therapy intervention designed to promote activity and independence and reduce falls, amongst people with early dementia or mild cognitive impairment

Detailed description

Background and study aims People with memory problems can struggle with everyday activities and may stop doing things they want to do. They are more prone to accidents and have a higher risk of falling. Occupational therapists can advise how to do daily activities more easily and safely. Physiotherapists can teach exercises which increase activity and improve balance, and may help maintain memory. There is little research on how to make these interventions work for with people with memory problems. The aim of this study is to compare an activity and exercise programme developed for people with memory problems to standard falls prevention assessment and advice. Who can participate? Patients aged 65 or over with early dementia or memory problems, recruited from memory clinics or the 'Join Dementia Research' register What does the study involve? Participants are randomly allocated to either the control group or the intervention group. The control group receive standard brief falls assessment and advice, and up to two further visits if required. The intervention group receive an assessment, tailored strength and balance exercise programme, activity analysis and risk enablement advice, and assessment for environmental hazards. The intervention is delivered over 1 year in participants' own homes, and is tailored to individual interests, abilities and need for supervision. Participants are encouraged to exercise by themselves or with family members between visits, and once the programme ends. Researchers visit at the start of the study and after 12 months to measure ability in activities of daily living, activity, quality of life, memory and health service use. Participants complete monthly falls diaries over 15 months. The researchers conduct interviews and video record some therapy sessions to help understand how the programme works in practice. What are the possible benefits and risks of participating? Some participants may benefit from taking part in the intervention, as exercise is generally known to be beneficial to health and well-being, including benefits to heart, blood pressure, diabetes, joints, mood and daily life. These participants may find that they are better able to do their daily activities. All participants and their relatives may enjoy having the researchers coming to visit them in their house. Some people appreciate having the opportunity to contribute to the well-being of others through research.

Interventions

BEHAVIORALIntervention

Assessment, tailored strength and balance exercise programme, activity analysis and risk enablement advice, and assessment for environmental hazards. Tailored adherence support and supervision.

Sponsors

National Institute for Health Research, United Kingdom
CollaboratorOTHER_GOV
Nottingham University Hospitals NHS Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Multi-centre, pragmatic, parallel-group, randomised controlled trial, with internal pilot trial, and embedded process and economic evaluations. Web-based randomisation, using a dynamic adaptive algorithm, stratified for centre and other variables to 1) active intervention or 2) standard brief falls assessment and advice. An internal pilot trial will recruit the first 50 participants.

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age 65 or over (no maximum) 2. Diagnosis of MCI or dementia (of any subtype, except Dementia with Lewy Bodies i.e. Parkinson's Disease Dementia) 3. Have a carer or friend who knows the participant well (at least one hour a week contact over the phone, internet, or in person), and is willing and able to act as an informant 4. Able to walk without human help 5. Able to communicate in English 6. Able to see, hear and have dexterity sufficiently to perform neuropsychological tests 7. Have capacity to give consent to participate, and consenting to do so

Exclusion criteria

1. Co-morbidity preventing participation (e.g. severe breathlessness, pain, psychosis, Parkinson's, Dementia with Lewy Bodies, or other severe neurological disease) 2. Unavailable over the next year (e.g. plans to relocate or go on a long holiday, or has a life expectancy of less than a year)

Design outcomes

Primary

MeasureTime frameDescription
Disability Assessment in Dementia (DAD)12 monthsPrimary outcomes will be disability in Activities of Daily Living (Disability Assessment in Dementia, DAD) measured 12 months after randomisation. This is as recommended in a recent NIHR systematic review \[Webster 2017\]. scale range is 0% to 100%. Where 0% = minimal functional ability and 100% maximal functional ability. Higher scores represent less disability in ADL and lower scores indicate more dysfunction. There are no subscales. The total score is obtained by adding the rating for each question and converting this total score out of 100. The items rated as N/A are not considered for the total score. For example: A score of 33 on 40 (maximum score) converted out of 100 = 83% A score of 33 on 38 (max. score with 2 N/A) converted out of 100 = 87% This will result in a final score, a percentage which provides an appreciation of global function in ADL. Higher scores represent less disability in ADL while lower scores indicate more dysfunction.

Secondary

MeasureTime frameDescription
Falls Rate12 monthsFalls rate in months four-15 from randomisation (defined as 'unintentionally coming to rest on the ground or at a lower level, however caused', and ascertained by monthly diary)
Quality of Life12 monthsQuality of life (EQ5D3L and EQ5D5L proxy \[EuroQol Group 1990\]; DemQol and DemQol proxy, including Demqol-u weights \[Smith 2005; Mulhern 2013\])
Mood or 'Affect'12 monthsMood or 'Affect' - Hospital Anxiety and Depression Scale (HADS \[Zigmond and Snaith 1983\]; Apathy Evaluation Scale - AES \[Marin, Biedrzycki and Firinciogullari 1991\])
Physical activity12 monthsLongitudinal Aging Study Amsterdam (LASA) physical activity questionnaire \[Stel 2004\], pedometers
Cognition12 monthsthree scales from CANTAB \[Cambridge Cognition, 2015\]; Montreal Cognitive Assessment - MoCA \[Nasreddine 2005\], verbal fluency (from MoCA)
Nottingham Extended ADL Scale12 monthsSelf-reported Activities of Daily Living (ADL) using the Nottingham Extended ADL Scale \[Nouri and Lincoln 1980\].
Rate of fractures and injurious falls12 monthsRate of fractures and injurious falls (from diary)
Rate of hospital and care home admissions, and days spent in hospital12 monthsRate of hospital and care home admissions, and days spent in hospital (from diary, hospital administrative records)
Carer strain12 monthsCarer strain (Carergiver Strain Index \[Robinson 1983\]).
Carer health-related quality of life12 monthsCarer health-related quality of life (EQ5D-5L \[EuroQol Group 1990\])
Personality12 monthsPersonality (Big Five Personality Inventory- short \[BFI-10, Rammstedt and John 2007\])
Time to first fall12 monthsTime to first fall (from diary)

Countries

United Kingdom

Contacts

Primary ContactSarah Goldberg, PhD
Sarah.Goldberg@nottingham.ac.uk01158230543
Backup ContactRowan Harward, PhD
Rowan.Harwood@nottingham.ac.uk01158230873

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026